Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease.

By better distinguishing amyloid changes during the post‐baseline follow‐up, LC analysis enables the analysis of surrogate endpoints in clinical trials in which the primary analysis did not achieve significance, but evidence suggests a clear impact on the primary target.

also in 1,397 other papers

Other clinical trials with anti‐amyloid drugs that did not fully remove amyloid did not reach statistical significance, although some exhibited small cognitive benefits in the expected direction. 13 , 25 This accumulating evidence presents an opportunity to better determine the amount of amyloid reduction that may serve as a surrogate biomarker and facilitate the acceleration of therapy development in this area.

also in 111,027 other papers